Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF -2.35%31 EV-to-OCF is -1.00 as of Aug. 15, 2026. GuruFocus rates CRDF with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Cardiff Oncology ranks worse than 63.83% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cardiff Oncology's Enterprise Value is $40.71 Mil.
Cardiff Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-40.85 Mil. Therefore, Cardiff Oncology's EV-to-OCF for today is -1.00.
The historical rank and industry rank for Cardiff Oncology's EV-to-OCF or its related term are showing as below:
CRDF'
s EV-to-OCF Range Over the Past 10 Years
Min: -33.33 Med: -0.66 Max: 2.59
Current: -1
During the past 13 years, the highest EV-to-OCF of Cardiff Oncology was 2.59. The lowest was -33.33. And the median was -0.66.
CRDF's EV-to-OCF is ranked worse than 63.83% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs CRDF: -1.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiff Oncology's PE Ratio (TTM) for today is calculated as:
Cardiff Oncology's share price for today is $0.9611.
Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cardiff Oncology EV-to-OCF Related Terms
Cardiff Oncology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's EV-to-OCF falls into.
Cardiff Oncology's current Enterprise Value is $40.71 Mil.
Cardiff Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a EV-to-OCF of -1.00 as of Aug. 15, 2026. According to the industry distribution chart, Cardiff Oncology ranks #900 out of 1410 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Cardiff Oncology's EV-to-OCF too high?
Cardiff Oncology's current EV-to-OCF is -1.00. Based on the distribution chart, Cardiff Oncology ranks #900 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's EV-to-OCF compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #900 out of 1410 companies for EV-to-OCF. This places Cardiff Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cardiff Oncology's current EV-to-OCF is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current EV-to-OCF of -1.00. The current EV-to-OCF is -1.00. Cardiff Oncology's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current EV-to-OCF is -1.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score
Get the complete analysis for CRDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
